Many thanks to Dan for his leadership of Emergent, his service as a loyal BHI Board Member and for helping accelerate the growth of the BIO Health Capital Region

Emergent BioSolutions Inc. (EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as president and CEO, effective April 1, 2019. Mr. Abdun-Nabi has also indicated that he plans to step down as a member of the Emergent board of directors, and Emergent expects the board of directors to appoint Mr. Kramer to fill the board vacancy created by Mr. Abdun-Nabi’s retirement.

Here is a significant opportunity for MARYLAND to grow in SBIR success.

One of the best ways to measure the effectiveness of state programs intended to encourage the success of SBIR applications is the approval-rate of their submissions. Although this data has been historically unavailable across every federal agency, it is now accessible for the National Institutes of Health (NIH), the second largest provider of SBIR/STTR awards, according to a 2018 Digest report. The NIH distributed $446.2 million in SBIR/STTR awards in 2017, with every state except North and South Dakota receiving an award. Although California and Massachusetts had the most successful SBIR/STTR applications in 2017, accounting for roughly one-third of the total when combined, neither state ranked among the top 10 in success rate.

A biotechnology venture capital firm is ringing in the new year with its latest fund, having raised a quarter of $1 billion.

Cambridge, Massachusetts-based Atlas Venture said Wednesday that it closed its first Opportunity Fund, or AVOF I, with an oversubscribed fund raise of $250 million. The firm plans to invest the money in companies already in its portfolio.

BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment

New Concussion-Specific FDA Labeling Adds to Existing BrainScope Claims Complements Multi-Modal Technology Platform and Extensive Intellectual Property Portfolio To Address New Brain and Behavioral Health Conditions

Tuesday, January 15, 2019 8:30AM - 10:30AM

GSK 9911 Belward Campus Drive Rockville, MD 20850

The Maryland Life Sciences, a division of the Maryland Tech Council, brings together vaccine leaders to discuss current breakthroughs in the world of vaccines and immunotherapeutics. This breakfast meeting will address innovating strategies to meet current health threats, changing technology for vaccine manufacturing and provide a snapshot of where vaccine development stands today.

Join us for breakfast, networking and a discussion to hear about the experiences and insights on the current state and projected future of treatments. Local leaders will also discuss challenges and opportunities that come with vaccine and immunotherapy development used by companies in our State.

Different places have different levels of educational achievement.

The American Community Survey is an annual survey run by the Census Bureau to allow the government, corporate and academic researchers, and anyone who is curious about demographics to better understand the US population. Among many other subjects, the ACS includes questions about respondents' education levels.

Though federal agencies are hungry for new technology solutions, a report from the Government Accountability Office says they may be missing out on a key avenue of innovation.

Having analyzed the trends and the shifting winds in the payer marketplace, it’s time to gaze into the crystal ball and see what the future has in store.

“If you can look into the seeds of time, and say which grain will grow and which will not, speak then unto me,” Banquo beseeches the witches in Shakespeare’s “Macbeth,” seeking insight into the future for himself and his closest friend Macbeth.

Peloton tops the list of NYC fund raisers in 2018, followed by WeWork and Letgo.

Though the healthcare field is notoriously slow to adopt new technologies, IT innovation is making its way to the sector. Looking ahead, what does the future of technology in the medical world look like? One hospital executive weighed in.

New funding will support Phase 1 studies for Spiral Therapeutics' lead drug candidate targeting inner ear disorders and hearing loss.

Baltimore startup emocha is working with a local healthcare organization on a new pilot that brings its mobile video technology to Type 2 diabetes patients in the city.

The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.

The Maryland Department of Commerce is seeking BioHealth companies with an interest in participating in a trade mission to the United Kingdom hosted by British Midlands Engine.

The University of Maryland, Baltimore has granted Educational & Scientific, LLC an exclusive license with the potential to treat prostate cancer, UM Ventures announced Monday. The agreement allows Educational & Scientific to develop Galeterone, a molecule that could inhibit prostate cancer growth in patients with castration-resistant prostate cancer. The molecule has had successful Phase 1 and Phase ...

Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks.

A startup developing new cancer treatments recently signed its second tech transfer deal with the University of Maryland, Baltimore.

After leading Harpoon Medical to a $100 million acquisition by Edwards Lifesciences last year, CEO Bill Niland and three other executives are now working on a fledgling medial device startup creating a minimally invasive treatment for degenerative disc disease in the lower back.

The research institute founded and headed by J. Craig Venter, Ph.D., yesterday won the dismissal of a federal lawsuit filed against it by the company he co-founded four years ago to develop and apply large-scale computing and machine learning toward making discoveries intended to revolutionize the practice of medicine. Judge William Q. Hayes of U.S. District Court for the Southern District of California sided with the J. Craig Venter Institute (JCVI) by dismissing the lawsuit brought against it by Human Longevity Inc. (HLI), the company Venter co-founded in 2014.

General Electric has filed paperwork for an IPO of its health-care unit, GE Healthcare, according to people familiar with the matter.

GE is working with JPMorgan Chase on an initial public offering that would likely come mid-2019, someone familiar with the plans told CNBC. Goldman Sachs, Bank of America, Citigroup and Morgan Stanley are also working with GE, according to Bloomberg News. The new public company would rank among the largest in the world.

State Tech and Science Index - 2018

It wouldn’t be a stretch to call 2018 the year RNA-based treatments, such as those applying RNA interference (RNAi) or small interfering RNA (siRNA), finally reached the proverbial tipping point predicted ever since Andrew Z. Fire and Craig C. Mello won the 2006 Nobel Prize in Physiology or Medicine for discovering RNAi.

Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its anthrax vaccine, BioThrax® (Anthrax Vaccine Adsorbed). BioThrax is indicated for active immunization for the prevention of disease caused by Bacillus anthracis, in individuals 18 through 65 years of age, whose occupation or other activities place them at risk of exposure, regardless of the route of exposure. BioThrax is administered in a three-dose primary schedule (0, 1 and 6 months) with boosters at three-year intervals recommended thereafter. BioThrax was approved under the Extraordinary Use New Drug Regulations, which provide a regulatory pathway for products for which collecting clinical information for its intended use in humans is logistically or ethically not possible.

A large chunk of the school's research spending — about $1.5 billion — can be attributed to Hopkins' Applied Physics Laboratory, based in Laurel.

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that the Eversense® Continuous Glucose Monitoring (CGM) System has been awarded one of Popular Science’s 2018 “Best of What’s New” Awards in the Health category.

The Maryland Stem Cell Research Fund provides a variety of grant programs for human stem cell research in the state of Maryland. Each RFA has its own timeline and review process; please read carefully the RFA when applying.

University of Maryland (UM) Ventures and Educational & Scientific, LLC (ESL) announced today that the University of Maryland, Baltimore (UMB) has again granted ESL an exclusive license for a novel cancer treatment. This agreement focuses on the development of Galeterone, a molecule with the potential to inhibit prostate cancer growth in patients with castration-resistant prostate cancer (CRPC). Galeterone is a steroidal antiandrogen that acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth.

BullFrog AI, Inc, a precision pharmaceutical company built around a powerful artificial intelligence (AI) platform, proudly announces the addition of executive Everett Lee as its Chief Technology Officer.  Mr. Lee brings nearly 3 decades of technical expertise and continuous advancement in technology management, strategic business planning and IT organizational leadership at major pharmaceutical/biotech and drug development companies such as AstraZeneca, Roche/Genentech, Eli Lilly & Co., Pfizer and Covance.

Intelligent nanobots offer the promise of smart drug delivery systems for a variety of therapeutic applications. A promise that experts in the field believe will become a reality within the next 30-40 years.

But at MedImmune, we don’t think patients should have to wait.

The idea of using patients’ own immune cells to fight cancer is over a hundred years old. In the late 19th century, an American doctor called William Coley attempted to treat cancer by stimulating the immune system with dangerous bacteria, arguably the first example of what is now known as immunotherapy. His procedure appeared to shrink some patients’ tumours, but was criticised as unsafe and largely forgotten about. Chemotherapy and radiotherapy became the focus of cancer research and the standard tumour treatment for the rest of the 20th century.

The former Belly Wine Bar and The Blue Room in Cambridge’s Kendall Square has been transformed into a biotech incubator.

The last time GEN compiled a list of CEOs, investors, and others with the biggest stakes in biopharma companies—what GEN calls “molecular millionaires”—was last year, based on 2016 data. Only one new person who had not been listed in previous editions made the cut back then.

This eighth, biennial report focuses on the economic progress and footprint of the industry geographically including the performance, positioning and latest trends in the bioscience industry for the nation, states and metropolitan areas. For the first time, it includes a national assessment of the full economic impact of the bioscience industry not only in terms of employment, but also with respect to economic output and fiscal impacts. In addition, the report details the nation’s academic research activities and trends in federal funding, access to critical angel and venture capital and the innovation outputs context via patent activities.

The Global Health Innovative Technology (GHIT) Fund has awarded VLP Therapeutics a $3.9 million grant to further develop a novel tetravalent dengue virus-like particle vaccine.